Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. J Manag Care Spec Pharm. 2017 May; 23(5):583-589.